Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | P4HB | P07237 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325284 | 1.00 | ALDH1A1 (0.68) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A | |
| SCHEMBL23251385 | 0.85 | MAPT (0.81) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A | |
| SCHEMBL9526011 | 0.84 | MAPT (0.64) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A | |
| SCHEMBL9526008 | 0.84 | MAPT (0.64) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A | |
| SCHEMBL19281407 | 0.83 | ALDH1A1 (0.72) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A | |
| SCHEMBL99941 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A | |
| SCHEMBL99942 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A | |
| SCHEMBL3563640 | 0.80 | CYP1A1 (0.61) | CYP1A1CYP1B1MAOBP4HB | |
| SCHEMBL3563636 | 0.80 | CYP1A1 (0.61) | CYP1A1CYP1B1MAOBP4HB | |
| SCHEMBL24119203 | 0.80 | CYP1A2 (1.00) | ALDH1A1CYP1A2CYP2C19MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119900035-A | Method for synthesizing 2, 5-disubstituted furan by C-C double bond cleavage free radical tandem electricity | 南京工业大学 | 2025-04-29 | — | — | CN | disclosed |
| CN-119874625-A | Synthesis method of pyrimidine compound promoted by visible light | 南通大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-119241430-A | Dihydroquinolines method for synthesizing compound | 无锡学院 | 2025-01-03 | — | — | CN | disclosed |
| CN-116240560-A | Method for electrochemically synthesizing furoquinone by utilizing microchannel reactor | 南京工业大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-108884047-B | Intermediates for the synthesis of aryl or heteroaryl substituted 5-hydroxy-1, 7-naphthyridine compounds and methods for their preparation | 沈阳三生制药有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-3287456-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3287456-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| CN-106146491-B | The naphthyridine compounds of 5 hydroxyl 1,7, its preparation method and its pharmaceutical applications being optionally substituted aryl or heteroaryl | 沈阳三生制药有限责任公司 | 2017-12-12 | — | — | CN | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| EP-1648896-B1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INT (ES) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007120593-A1 | ANILINO-PYRIMIDINE PHENYL AND BENZOTHIOPHENE ANALOGS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1799652-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | Wyeth (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007028132-A2 | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | FERRER INTERNACIONAL S.A. (ES) | 2007-02-22 | — | — | US | disclosed |
| WO-2006044457-A1 | N-BENZENESULFONYL SUBSTITUTED ANILINO-PYRIMIDINE ANALOGS | WYETH (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214520-A1 | 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3B, HTR1A | ALDH1A1 407/4885CYP1A2 216/4885CYP2C19 173/4885 |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | GABRB1, GABRA1, GABRB2 | ALDH1A1 113/4885CYP1A2 71/4885CYP2C19 282/4885 |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | ALDH1A1 119/4885CYP1A2 29/4885CYP2C19 64/4885 |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | ALDH1A1 793/4885CYP1A2 255/4885CYP2C19 179/4885 |
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | ALDH1A1 1072/4885CYP1A2 733/4885CYP2C19 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.